Abstract:Background and objective: Osteosarcoma is a common primary malignant tumor of bone, and doxorubicin is one of the most widely used therapeutic drugs. While the problem of doxorubicin resistance limits the long-term treatment benefits in osteosarcoma patients. The role of miRNAs and their target genes in osteosarcoma have become increasingly prominent. Currently, there is no report on miR-506-3p reversing doxorubicin resistance by targeting STAT3 in osteosarcoma. The purpose of this study was to investigate the molecular mechanism that overexpression of miR-506-3p reverses doxorubicin resistance in drug-resistant osteosarcoma cells. Methods: Doxorubicin-resistant osteosarcoma cells (U-2OS/Dox) were constructed by intermittent stepwise increasing stoichiometry. The target genes of miR-506-3p were predicted by bioinformatics approach and the targeting relationship between miR-506-3p and STAT3 was detected using dual luciferase reporter assay. U-2OS/Dox cells were treated with miR-506-3p overexpression and STAT3 silencing respectively. Then Western blot and RT-qPCR were used to detect the protein and mRNA expression levels of JAK2/STAT3 signaling pathway, drug-resistant and apoptotic associated molecules. The migration and invasion were assessed by cell scratch assay and transwell assay. The cell proliferative viability and apoptosis were investigated by CCK8 assay and flow cytometry assay. Results: U-2OS/Dox cells were successfully constructed with a 14.4-fold resistance. MiR-506-3p is directly bound to the 3′-UTR of STAT3 mRNA. Compared with U-2OS cells, the mRNA expression of miR-506-3p was reduced in U-2OS/Dox cells. Overexpression of miR-506-3p decreased the mRNA expression levels of JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and decreased the protein expression levels of p-JAK2, STAT3, MDR1/ABCB1, MRP1/ABCC1, Survivin and Bcl-2, and conversely increased Bax expression. It also inhibited the proliferation, migration and invasion of U-2OS/Dox cells and promoted cells apoptosis. The results of STAT3 silencing experiments in the above indicators were consistent with that of miR-506-3p overexpression. Conclusion: Overexpression of miR-506-3p could inhibit the JAK2/STAT3 pathway and the malignant biological behaviors, then further reverse doxorubicin resistance in drug-resistant osteosarcoma cells. The study reported a new molecular mechanism for reversing the resistance of osteosarcoma to doxorubicin chemotherapy and provided theoretical support for solving the clinical problems of doxorubicin resistance in osteosarcoma.

The Survivin Suppressant YM155 Reverses Doxorubicin Resistance in Osteosarcoma.

Ym155 Exerts A Growth Inhibitory Effect on Human Osteosarcoma in Vitro and in Vivo

YM155 Enhances Docetaxel Efficacy in Ovarian Cancer.

Enhanced Chemosensitivity by Simultaneously Inhibiting Cell Cycle Progression and Promoting Apoptosis of Drug-Resistant Osteosarcoma Mg63/Dxr Cells by Targeting Cyclin D1 and Bcl-2

Combination Therapy with Bioengineered Mir-34A Prodrug and Doxorubicin Synergistically Suppresses Osteosarcoma Growth.

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Sensitization of Osteosarcoma Cell Line SaOS-2 to Chemotherapy by Downregulating Survivin.

The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma

Antisense Oligonucleotide Targeting Survivin Inhibits Growth by Inducing Apoptosis in Human Osteosarcoma Cells Mg-63

Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis

Stathmin is Key in Reversion of Doxorubicin Resistance by Arsenic Trioxide in Osteosarcoma Cells.

Antitumor Effects of Combining Doxorubicin Hydrochloride with Recombinant Human Endostatin in an Osteosarcoma Model

Enhanced Chemosensitivity of Drug-Resistant Osteosarcoma Cells by Lentivirus-Mediated Bcl-2 Silencing

The Over-Expression of Survivin Enhances the Chemotherapeutic Efficacy of YM155 in Human Hepatocellular Carcinoma

The Mechanism of Radiosensitization by YM155, a Novel Small Molecule Inhibitor of Survivin Expression, is Associated with DNA Damage Repair

Promotion of Ubiquitination-Dependent Survivin Destruction Contributes to Xanthohumol-Mediated Tumor Suppression and Overcomes Radioresistance in Human Oral Squamous Cell Carcinoma.

Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.

Ovarian Primary and Metastatic Tumors Suppressed by Survivin Knockout or a Novel Survivin Inhibitor

Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways

Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells

Sorafenib Inhibits Doxorubicin-Induced PD-L1 Upregulation to Improve Immunosuppressive Microenvironment in Osteosarcoma